FDA Recognition Triggers Major Surge In Mustang Bio (MBIO) Stock
The shares of Mustang Bio, Inc. (NASDAQ: MBIO) surged 180.67% on Monday, closing at $3.34, following the announcement of a major regulatory milestone. The increase followed the announcement that the U.S. Food and Drug Administration (FDA) has designated MB-101, MBIO’s investigational IL13Ra2-targeted CAR T-cell treatment, as an Orphan Drug to treat glioblastoma (GBM) and recurrent […]